Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04877483
Other study ID # 2020-07-003C
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 6, 2022
Est. completion date December 31, 2024

Study information

Verified date December 2022
Source Taipei Veterans General Hospital, Taiwan
Contact Chang Ching-Mao, M.D., Ph.D.
Phone 886-28757453
Email magicbjp@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study wants to use a randomized, single-blind, controlled trial to evaluate the efficacy of receiving acupuncture GB20 or GB20 plus BL2 on alleviating the ocular dryness symptom from dry eye syndrome and Sjögren's syndrome. One hundred dry eye syndrome subjects are composed of 50 dry eye syndrome subjects and 50 Sjögren's syndrome' dry eye subjects, and all are randomized into 40 Group GB20 and 40 Group GB20 plus BL2 (GBL), and 20 Group Waiting list; while we also include 20 healthy controls. Fifty dry eye syndrome subjects are randomized into 20 Group GB20, 20 Group GBL and 10 Group Waiting list in first year; while both Group GB20 or GBL received acupuncture twice a week 8 weeks for efficacy evaluation, and 10 Group Waiting list receive no any acupuncture treatment. And we could use the Whole-genome genotyping, oral microbiota, Schirmer's test, Tear breakup time, Cytokines, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose. In second year, another 50 dry eye syndrome subjects are also enrolled and randomized into randomized into 20 Group GB20, 20 Group GBL and 10 Group Waiting list; while both Group GB20 or GBL received acupuncture twice a week 8 weeks for efficacy evaluation with above outcome measurements, and 10 Group Waiting list receive no any acupuncture treatment. Meanwhile, we also include 20 healthy controls, and we want to find the difference with the comparison between the dry eye syndrome, Sjögren's syndrome and healthy control in second year. Through the analysis for dry eye syndrome and Sjögren's syndrome, we could find the biomarker to differentiate dry eye syndrome, Sjögren's syndrome and healthy control. In the future, this work could be applied for screening and diagnosis of pre-dry eye syndrome and Sjögren's syndrome, and this integrated TCM with Western Medicine plan could be applied for the goal of holistic health care.


Description:

Method: This study wants to use a randomized, single-blind, controlled trial to evaluate the efficacy of receiving acupuncture GB20 or GB20 plus BL2 on alleviating the ocular dryness symptom from dry eye syndrome and Sjögren's syndrome. One hundred dry eye syndrome subjects are composed of 50 dry eye syndrome subjects and 50 Sjögren's syndrome' dry eye subjects, and all are randomized into 40 Group GB20 and 40 Group GB20 plus BL2 (GBL), and 20 Group Waiting list; while we also include 20 healthy controls. Fifty dry eye syndrome subjects are randomized into 20 Group GB20, 20 Group GBL and 10 Group Waiting list in first year; while both Group GB20 or GBL received acupuncture twice a week 8 weeks for efficacy evaluation, and 10 Group Waiting list receive no any acupuncture treatment. And we could use the Whole-genome genotyping, oral microbiota, Schirmer's test, Tear breakup time, Cytokines, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose. In second year, another 50 dry eye syndrome subjects are also enrolled and randomized into randomized into 20 Group GB20, 20 Group GBL and 10 Group Waiting list; while both Group GB20 or GBL received acupuncture twice a week 8 weeks for efficacy evaluation with above outcome measurements, and 10 Group Waiting list receive no any acupuncture treatment. Meanwhile, we also include 20 healthy controls, and we want to find the difference with the comparison between the dry eye syndrome, Sjögren's syndrome and healthy control in second year. Through the analysis for dry eye syndrome and Sjögren's syndrome, we could find the biomarker to differentiate dry eye syndrome, Sjögren's syndrome and healthy control. In the future, this work could be applied for screening and diagnosis of pre-dry eye syndrome and Sjögren's syndrome, and this integrated TCM with Western Medicine plan could be applied for the goal of holistic health care. Expected Results: 1. To evaluate the difference among Schirmer's test, TBUT, TCM pattern, TCM tongue diagnosis, TCM pulse diagnosis, heart rate variability, Whole-genome genotyping, oral microbiota, and Cytokines for dry eye syndrome, Sjögren's syndrome and healthy control. 2. Integrated functional multi-omics for dry eye syndrome and healthy control. 3. To evaluate the efficacy of GB20 plus BL2 for dry eye syndrome and Sjögren's syndrome. 4. To evaluate the efficacy of GB20 for dry eye syndrome and Sjögren's syndrome. 5. To evaluate the efficacy of BL2 for dry eye syndrome and Sjögren's syndrome. Keywords: Dry eye syndrome, Sjögren's syndrome, Xerophthalmia, Acupuncture, GB20, BL2


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 31, 2024
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility - Dry eye syndrome - Inclusion Criteria: 1. aged between 20 and 75 years 2. Schirmer's test less than 10 mm/5 min - Exclusion Criteria: 1. Pregnancy 2. With eye inflammation or infectious eye disease 3. Accepted operation of eye - Sjögren's syndrome - Inclusion Criteria: 1. primary or secondary SS 2. aged between 20 and 75 years 3. fulfilled the 2002 American-European Consensus Criteria for SS (AECG) 4. had no abnormal findings of immune, liver, kidney, or blood function evaluations. - Exclusion Criteria: 1. a history of alcohol abuse, diabetes mellitus, or major life-threatening condition 2. pregnancy or breastfeeding 3. steroid pulse therapy within three months prior to the commencement of our study.

Study Design


Intervention

Procedure:
Acupuncture
Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
Diagnostic Test:
Oral microbiota
Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
Schirmer's test
Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
Tear breakup time
Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
OSDI(Ocular Surface Disease Index)
Group GB20 and Group GB20 plus BL2 will take the OSDI test.
TCM pattern
Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
Traditional Chinese Medicine (TCM) tongue diagnosis
Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
TCM pulse diagnosis
Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
TCM heart rate variability
Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)
Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
Whole-genome genotyping(TWBv2.0)
Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
Cytokine markers
Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17?MMP-9?BAFF?BCMA) analysis.
Blood biochemical analysis
Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
complete blood count (CBC)
Group GB20 and Group GB20 plus BL2 will take the CBC(WBC?RBC?Hb?Platelet) analysis.
SF-36(36-Item Short Form Survey )
Group GB20 and Group GB20 plus BL2 will take the SF-36 test.

Locations

Country Name City State
Taiwan Ching-Mao Chang Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Schirmer's test Schirmer's test is a tool for evaluating aqueous tear production among the dry eye syndrome. one year
Primary OSDI(Ocular Surface Disease Index) OSDI(Ocular Surface Disease Index) is a tool to rate the severity of dry eye disease among the dry eye syndrome. one year
Secondary TCM pattern TCM pattern is a tool for detecting the constitution among the Dry eye syndrome (DES) and healthy control. one year
Secondary TCM tongue diagnosis TCM tongue diagnosis is a tool for detecting tongue expression among the Dry eye syndrome (DES) and healthy control. one year
Secondary Heart rate variability (HRV) Heart rate variability (HRV) is a tool for detecting ratio betwee n High-frequency (HF) activity and low-frequency (LF) activity among the Dry eye syndrome (DES) and healthy control. one year
Secondary TCM pulse diagnosis TCM tongue diagnosis is a tool for detecting tongue expression pulse pattern among the Dry eye syndrome (DES) and healthy control. one year
Secondary SF-36(36-Item Short Form Survey ) SF-36 is a tool for evaluating Health-Related Quality of Life among the Dry eye syndrome (DES). one year
Secondary ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index) ESSPRI is a tool for evaluating the symptoms of SJS among the dry eye syndrome. one year
Secondary Tear breakup time (TBUT) Tear breakup time (TBUT) is a clinical test used to assess for evaporative dry eye disease. one year
Secondary Whole-genome genotyping(TWBv2.0) By using the Whole-genome genotyping(TWBv2.0) of the immune-relate gene(RF5,TNIP1 (TNFAIP3),FCGR2B,TNF,LTA,NFKBIA,STAT4,IL-1ß,IL-1R,IL-6,IL-6R,IL-8,IL-8R,IL-10,IL-10R,IL-12,IL-12R,IL-17,IL-17R,IL-18,IL-18R,IL-23,IL-23R,IL-27,IL-27R,TGF-ß1,IFN-a,IFN-aR,IFN-?,IFN-?R,TNFRSF4,BLK,CXCR5,CXCL10 to find the difference with the comparison between the dry eye syndrome and healthy control. one year
Secondary Oral microbiota By using the Oral microbiota analysis to find the difference with the comparison between the dry eye syndrome and healthy control. one year
Secondary Blood biochemical analysis By using the blood biochemical analysis of BUN,Cre,AST,ALT,CRP and ESR to evaluate the liver function and renal function among the Dry eye syndrome. one year
Secondary Cytokine biomarkers By using cytokine biomarkers analysis of IL-17,MMP-9,BAFF and BCMA to find the difference with the comparison between the dry eye syndrome and healthy control. one year
Secondary CBC(complete blood count) A complete blood count (CBC) is a blood test used to evaluate overall health among the Dry eye syndromes. one year
See also
  Status Clinical Trial Phase
Completed NCT02522312 - A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients N/A
Completed NCT02597803 - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Phase 2/Phase 3
Completed NCT01863368 - Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining N/A
Completed NCT01753752 - Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation Phase 2
Completed NCT01753687 - Correlation of Different Signs for Assessment of Dry Eye Syndrome N/A
Completed NCT01198782 - Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Phase 4
Completed NCT01212471 - A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease Phase 3
Completed NCT01162954 - Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Phase 1
Completed NCT00535054 - Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms N/A
Completed NCT00544713 - Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery N/A
Completed NCT00344721 - A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome N/A
Completed NCT03830359 - Efficacy, Safety of T2769 in Dry Eye Disease N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Completed NCT02758327 - Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Phase 4
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Completed NCT01970917 - Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Phase 4
Completed NCT02092207 - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome Phase 2
Completed NCT01541891 - Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome Phase 2
Completed NCT01252121 - Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline N/A
Completed NCT00765804 - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye Phase 2